GlassScriptPhysician profile
Michael Dan Duncan
NPI 1396793758
$15,847.55
in general payments reported to CMS, 2019-2025
11 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.48 · 2020: $47.95 · 2021: $13K · 2022: $290 · 2023: $2,476 · 2024: $139 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Travel and Lodging: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.14 |
| Travel and Lodging | $1,090.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $12,670.20 | 2021 | |
| Medtronic, INC. | $1,357.24 | 2023 | Mc3 Nautilus(Tm) Ecmo Oxygenator, Bio-Console, Trillium Affinity Nt |
| Actelion Pharmaceuticals US, INC. | $839.48 | 2022-2023 | Opsumit, Uptravi |
| United Therapeutics Corporation | $555.89 | 2023-2025 | Tyvaso, Orenitram, Remodulin |
| Intuitive Surgical, INC. | $157.74 | 2022 | |
| Abbott Laboratories | $134.20 | 2023 | 2nd Gen Centrimag Primary Console |
| Genentech USA, INC. | $47.95 | 2020 | |
| Novo Nordisk INC | $33.56 | 2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $27.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.